PML-RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-talk in Acute Promyelocytic Leukemia Cell Differentiation

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2004 Apr 21

PMID 15096541

Citations 51

Authors

Dmitrii Kamashev

Dominique Vitoux

Hugues de The

Affiliations

Soon will be listed here.

Abstract

PML-RARA was proposed to initiate acute promyelocytic leukemia (APL) through PML-RARA homodimer-triggered repression. Here, we examined the nature of the PML-RARA protein complex and of its DNA targets in APL cells. Using a selection/amplification approach, we demonstrate that PML-RARA targets consist of two AGGTCA elements in an astonishing variety of orientations and spacings, pointing to highly relaxed structural constrains for DNA binding and identifying a major gain of function of this oncogene. PML-RARA-specific response elements were identified, which all conveyed a major transcriptional response to RA only in APL cells. In these cells, we demonstrate that PML-RARA oligomers are complexed to RXR. Directly probing PML-RARA function in APL cells, we found that the differentiation enhancer cyclic AMP (cAMP) boosted transcriptional activation by RA. cAMP also reversed the normal silencing (subordination) of the transactivating function of RXR when bound to RARA or PML-RARA, demonstrating that the alternate rexinoid/cAMP-triggered APL differentiation pathway also activates PML-RARA targets. Finally, cAMP restored both RA-triggered differentiation and PML-RARA transcriptional activation in mutant RA-resistant APL cells. Collectively, our findings directly demonstrate that APL cell differentiation parallels transcriptional activation through PML-RARA-RXR oligomers and that those are functionally targeted by cAMP, identifying this agent as another oncogene-targeted therapy.

Citing Articles

PML::RARA and GATA2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells.

Katerndahl C, Rogers O, Day R, Xu Z, Helton N, Ramakrishnan S Proc Natl Acad Sci U S A. 2024; 121(18):e2317690121.

PMID: 38648485 PMC: 11067031. DOI: 10.1073/pnas.2317690121.

History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies.

Bercier P, de The H Cancers (Basel). 2024; 16(7).

PMID: 38611029 PMC: 11011038. DOI: 10.3390/cancers16071351.

Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia.

Villiers W, Kelly A, He X, Kaufman-Cook J, Elbasir A, Bensmail H Nat Commun. 2023; 14(1):724.

PMID: 36759620 PMC: 9911410. DOI: 10.1038/s41467-023-36262-0.

A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis.

Thrun M, Mack E, Neubauer A, Haferlach T, Frech M, Ultsch A Bioengineering (Basel). 2022; 9(11).

PMID: 36354555 PMC: 9687378. DOI: 10.3390/bioengineering9110642.

History of Acute Promyelocytic Leukemia.

Sanz M, Barragan E Clin Hematol Int. 2021; 3(4):142-152.

PMID: 34938986 PMC: 8690702. DOI: 10.2991/chi.k.210703.001.

References

Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld M . Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature. 1995; 377(6548):451-4. DOI: 10.1038/377451a0. View

Jansen J, Mahfoudi A, Rambaud S, Lavau C, Wahli W, Dejean A . Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci U S A. 1995; 92(16):7401-5. PMC: 41347. DOI: 10.1073/pnas.92.16.7401. View

Castelein H, Janssen A, Declercq P, Baes M . Sequence requirements for high affinity retinoid X receptor-alpha homodimer binding. Mol Cell Endocrinol. 1996; 119(1):11-20. DOI: 10.1016/0303-7207(96)03794-x. View

Zhu J, Koken M, Quignon F, Chelbi-Alix M, Degos L, Wang Z . Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997; 94(8):3978-83. PMC: 20553. DOI: 10.1073/pnas.94.8.3978. View

Shao W, Benedetti L, Lamph W, Nervi C, Miller Jr W . A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood. 1997; 89(12):4282-9. View

Taneja R, Rochette-Egly C, Plassat J, Penna L, Gaub M, Chambon P . Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO J. 1997; 16(21):6452-65. PMC: 1170251. DOI: 10.1093/emboj/16.21.6452. View

He L, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A . Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998; 18(2):126-35. DOI: 10.1038/ng0298-126. View

Lin R, Nagy L, Inoue S, Shao W, Miller Jr W, Evans R . Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998; 391(6669):811-4. DOI: 10.1038/35895. View

De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M . Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998; 391(6669):815-8. DOI: 10.1038/35901. View

10.

Gianni M, Koken M, Chelbi-Alix M, Benoit G, Lanotte M, Chen Z . Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 1998; 91(11):4300-10. View

11.

Subauste J, Koenig R . Characterization of the DNA-binding and dominant negative activity of v-erbA homodimers. Mol Endocrinol. 1998; 12(9):1380-92. DOI: 10.1210/mend.12.9.0167. View

12.

Quenechdu N, Ruchaud S, Khelef N, Guiso N, Lanotte M . A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels. Leukemia. 1998; 12(11):1829-33. DOI: 10.1038/sj.leu.2401171. View

13.

Guillemin M, Janin A, Daniel M, Degos L, Kogan S, Bishop J . Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999; 189(7):1043-52. PMC: 2193002. DOI: 10.1084/jem.189.7.1043. View

14.

Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raffelsberger W . RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 1999; 18(24):7011-8. PMC: 1171764. DOI: 10.1093/emboj/18.24.7011. View

15.

Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M . Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A. 1999; 96(26):14807-12. PMC: 24729. DOI: 10.1073/pnas.96.26.14807. View

16.

Duprez E, Benoit G, Flexor M, Lillehaug J, Lanotte M . A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia. 2000; 14(2):255-61. DOI: 10.1038/sj.leu.2401683. View

17.

Kogan S, Hong S, Shultz D, Privalsky M, Bishop J . Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood. 2000; 95(5):1541-50. View

18.

Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S . Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000; 5(5):811-20. DOI: 10.1016/s1097-2765(00)80321-4. View

19.

Lin R, Evans R . Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell. 2000; 5(5):821-30. DOI: 10.1016/s1097-2765(00)80322-6. View

20.

Rego E, He L, Warrell Jr R, Wang Z, Pandolfi P . Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A. 2000; 97(18):10173-8. PMC: 27786. DOI: 10.1073/pnas.180290497. View